Department of Chemical and Biomolecular Engineering, Ohio University, Athens, OH, 45701, USA.
Department of Specialty Medicine, Ohio University, Athens, OH, 45701, USA.
Sci Rep. 2024 May 16;14(1):11179. doi: 10.1038/s41598-024-61906-6.
During a SARS-CoV-2 infection, macrophages recognize viral components resulting in cytokine production. While this response fuels virus elimination, overexpression of cytokines can lead to severe COVID-19. Previous studies suggest that the spike protein (S) of SARS-CoV-2 can elicit cytokine production via the transcription factor NF-κB and the toll-like receptors (TLRs). In this study, we found that: (i) S and the S2 subunit induce CXCL10, a chemokine implicated in severe COVID-19, gene expression by human macrophage cells (THP-1); (ii) a glycogen synthase kinase-3 inhibitor attenuates this induction; (iii) S and S2 do not activate NF-κB but do activate the transcription factor IRF; (iv) S and S2 do not require TLR2 to elicit CXCL10 production or activate IRF; and (v) S and S2 elicit CXCL10 production by peripheral blood mononuclear cells (PBMCs). We also discovered that the cellular response, or lack thereof, to S and S2 is a function of the recombinant S and S2 used. While such a finding raises the possibility of confounding LPS contamination, we offer evidence that potential contaminating LPS does not underly induced increases in CXCL10. Combined, these results provide insights into the complex immune response to SARS-CoV-2 and suggest possible therapeutic targets for severe COVID-19.
在 SARS-CoV-2 感染期间,巨噬细胞识别病毒成分导致细胞因子的产生。虽然这种反应有助于消除病毒,但细胞因子的过度表达可能导致严重的 COVID-19。先前的研究表明,SARS-CoV-2 的刺突蛋白(S)可以通过转录因子 NF-κB 和 Toll 样受体(TLRs)引发细胞因子的产生。在这项研究中,我们发现:(i)S 和 S2 亚基诱导人巨噬细胞(THP-1)中细胞因子 CXCL10 的基因表达,该细胞因子与严重的 COVID-19 有关;(ii)糖原合成酶激酶-3 抑制剂可减弱这种诱导;(iii)S 和 S2 不激活 NF-κB,但激活转录因子 IRF;(iv)S 和 S2 不需要 TLR2 引发 CXCL10 产生或激活 IRF;(v)S 和 S2 引发外周血单核细胞(PBMCs)中 CXCL10 的产生。我们还发现,对 S 和 S2 的细胞反应或缺乏反应是使用重组 S 和 S2 的功能。虽然这一发现增加了 LPS 污染的可能性,但我们提供的证据表明,潜在的污染 LPS 不是 CXCL10 增加的基础。综上所述,这些结果提供了对 SARS-CoV-2 复杂免疫反应的深入了解,并为严重 COVID-19 提供了可能的治疗靶点。